Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs eMed

Claya
Graded #268

Higher grade

vs+5.399999999999999
eMed
Graded #399

Lower grade

The verdict

Claya takes it — 62.8/100 to 57.4/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueeMed +3
42
45
Dose & formulationClaya +35
75
40
Clinical oversighteMed +1
82
83
Labs & monitoringeMed +12
53
65
FulfillmentClaya +5
67
62
Contract termsClaya +6
61
55
Claya · left bareMed · right bar

The numbers

MetricClayaeMed
WeighScore62.8/10057.4/100
GradeCC
Scorecard rank#268#399
Semaglutide$299/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
eMed

Graded #399 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
  • At-home blood collection makes lab work convenient
  • Clinician review and ongoing side-effect plus adherence support
  • Works with CVS Caremark so eligible employees can buy through benefits
  • Established digital health company with national scale

Where it loses points

  • Distributed mainly via employers, with limited direct cash-pay access
  • No public transparent monthly price for individuals
  • Eligibility and subsidy depend on what the employer chooses to cover
  • Best suited to workforces, not casual self-pay shoppers

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard